Fentanyl law broadens drug crimes while cutting sentences for past convictions
H.R. 830 — SAFE Act · Filed by Chris Pappas (D-NH) · 17 cosponsors · Introduced Jan 31, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a permanent legal category for fentanyl-related substances (any chemical structurally similar to fentanyl) and places them all in Schedule I of the Controlled Substances Act. It removes mandatory minimum sentences based on drug quantity for these substances, allows researchers easier access to study them, and permits courts to reduce sentences for people previously convicted under now-outdated fentanyl analogue laws.
Why we flagged it
The bill's core mechanism is a permanent class scheduling of fentanyl analogues combined with sentencing relief and research facilitation. It is primarily a criminal-justice and drug-policy measure, not a market-driven carve-out.
What the text implies
- The 'fentanyl-related substance' definition is structural, not pharmacological—it may capture compounds with no abuse potential or medical utility before they are studied, creating a regulatory trap for researchers and pharmaceutical developers.
- Sentence reduction is discretionary ('may' vacate), not mandatory, leaving relief dependent on individual judges' willingness to revisit old cases—creating unequal outcomes across districts.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies developing fentanyl-derivative treatments; research institutions conducting federally-funded opioid research